Risks

Patent expirations for Humira and later Skyrizi/Rinvoq create a multi-year revenue reset, but AbbVie’s diversified immunology and aesthetics mix should soften the decline versus narrower specialty peers.

U.S. pricing pressure and IRA negotiation exposure can compress branded-drug margins, yet AbbVie’s scale and premium portfolio leave it better positioned than smaller single-asset biopharma peers.

Leverage remains elevated with net debt to EBITDA near 3.0x and interest coverage above 6x, which constrains financial flexibility more than for lower-levered large-cap pharma peers.

Working-capital intensity and a sub-1.0 current ratio increase refinancing and liquidity sensitivity, although AbbVie’s recurring cash generation is still stronger than many development-stage peers.

Opportunities

Skyrizi and Rinvoq continue to offset Humira erosion, and their growth runway gives AbbVie better near-term revenue visibility than peers facing single-product patent cliffs.

The aesthetics franchise, led by Botox and related brands, provides a differentiated consumer-health growth vector that is less exposed to payer pressure than core pharma peers.

AbbVie’s broad immunology leadership supports pricing and formulary resilience, which should help preserve share versus smaller competitors with weaker launch breadth.

Pipeline and lifecycle management across oncology and neuroscience can extend growth beyond the current franchise cycle, offering more optionality than peers with fewer late-stage assets.

Overall Score

AbbVie’s forward positioning is strong because Skyrizi, Rinvoq, and aesthetics provide credible offset to Humira-related erosion, while leverage and patent-cliff risk remain the main constraints versus peers.